Biotechnology - InterMune

Filter

Current filters:

InterMune

Popular Filters

US breakthrough status for InterMune’s pirfenidone

US breakthrough status for InterMune’s pirfenidone

21-07-2014

US biotech firm InterMune’s Esbriet (pirfenidone) has been granted Breakthrough Therapy designation…

BiotechnologyEsbrietFood and Drug AdministrationInterMunepirfenidoneRare diseasesRegulationRespiratory and PulmonaryUSA

Strong new data for InterMune’s Esbriet sees the firm’s stock rocket

26-02-2014

US biotech firm InterMune has released top-line data from ASCEND, a Phase III trial evaluating pirfenidone…

BiotechnologyEsbrietInterMuneResearchRespiratory and Pulmonary

Ireland's HSE to reimburse InterMune's Esbriet for IPF

08-07-2013

US biotech firm InterMune's (Nasdaq: ITMN) UK subsidiary says that Ireland's Health Service Executive…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

Pricing and reimbursement conditions for InterMune's Esbriet in Italy

17-06-2013

US biotech firm InterMune (Nasdaq: ITMN) says that the board of the Italian Drug Agency (AIFA) has approved…

BiotechnologyEsbrietEuropeInterMunePricingRespiratory and Pulmonary

New idiopathic pulmonary fibrosis treatment may open up valuable research opportunity, says GlobalData

17-04-2013

Further research is a prerequisite to shine a light on idiopathic pulmonary fibrosis (IPF) and offer…

BiotechnologyEsbrietInterMunePricingRare diseasesRegulationResearch

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

UK's NICE initially negative on InterMune's Esbriet for idiopathic pulmonary fibrosis

30-11-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) said yesterday that…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

InterMune to divest Actimmune for $55 million; to focus on Esbriet

22-05-2012

California, USA-based biotech firm InterMune (Nasdaq: ITMN) says that it has reached a definitive agreement…

ActimmuneBiotechnologyEsbrietFinancialImmunologicalsInterMuneMergers & AcquisitionsRespiratory and PulmonaryVidara Therapeutics

Back to top